A Phase II Exploratory, Multicentre, Open-label, Non-comparative Study of ZD1839 (Iressa) and Radiotherapy in the Treatment of Patients With Glioblastoma Multiforme

Inclusion Criteria: * Signed informed consent * histologically-or cytologically-confirmed glioblastoma multiforme * age 18 years or older Exclusion Criteria: * Have had prior radiation therapy, immunotherapy, gene therapy and/or chemotherapy for the glioblastoma * co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ * known severe hypersensitivity to ZD1839 or any of the excipients of this product.